
AMBULATORY CARE PLAN



ASSESSMENT of POSSIBLE LOWER LIMB DVT in PATIENTS WHO PRESENT to HOSPITAL



IN CASES OF ONGOING CLINICAL CONCERN OF DVT DESPITE INVESTIGATION DO NOT DISCHARGE.
CHECK WITH A SENIOR DOCTOR. CASE MAY MERIT FURTHER DISCUSSION WITH RADIOLOGY AND HAEMATOLOGY TO DECIDE
ON FURTHER IMAGING AND/OR TREATMENT.

AMBULATORY CARE PLAN



MANAGEMENT of CONFIRMED DVT

All patients

- Ensure all patents have had baseline blood tests including FBC, U+E, glucose, calcium, LFTs, coagulation, urinalysis and chest x-ray
- Check pregnancy test in all women of child bearing age and refer to Obstetric team if positive
- Ensure all females have had a cervical screening if appropriate and do a breast exam.
- Consider further imaging to look for underlying pathology depending on clinical suspicion and discuss this with radiology prior to making the request.
- Do not routinely prescribe TED stockings unless for symptom control on follow up. Refer to NHS Lothian Antithrombotic Guideline for contraindications.
- Ensure patient given advice on exercises and elevation. (Gentle walking for 6 weeks, leg elevated when resting)
- Give patient DVT information booklet and advise to seek medical attention if symptoms of PE or worsening leg symptoms

Decide if patient requires admission Social circumstances or co-morbid illness necessitating admission Severe pain, swelling and discolouration of the leg suggestive of phlegmasia cerulea dolens. Discuss such Admit Admit for anticoagulation cases with Haematology and Vascular Surgery regarding further intervention. and other treatment as Increased risk of bleeding necessitating IV heparin therapy and monitoring appropriate Creatinine clearance <30 mls/min (Use NHSL creatinine clearance calculator available on the intranet) -Need discussion with senior doctor to decide if for admission to hospital or ongoing management in ambulatory care and if for IV heparin or Dalteparin with LMWH levels or Apixaban. **Ambulate** Yes Does patient have active cancer? Refer to the Edinburgh Cancer Centre Antithrombotic Guideline on the Oncology Online Quality System intranet site to decide on anticoagulation. LMW Heparin therapy Does patient have? Patient treated with daily Dalteparin injections Yes Active alcohol or drug abuse Complete Dalteparin counselling Significant falls risk Discharge to GP once agreed that they will prescribe further Dalteparin and a safe means of administration has been organised No Anti-Xa levels may be indicated in obesity, renal impairment. Can patient be treated with Apixaban? Follow up at 6 weeks for review and to decide on duration of therapy Weight > 50 kg and <120kg (for body weight >120Kg discuss with Prescribe Apixaban senior doctor as off label LMWH dosing and LMWH monitoring may be See Apixaban Prescribing Guidance including Prescriber Information, Counselling and GP letter Cognitively intact (or adequate carer support) Ensure patient has Apixaban counselling Yes Acceptable kidney function (Creatinine Clearance ≥ 15mls/min) For patients with venous thrombosis Apixaban should be Use NHSL creatinine clearance calculator available on the intranet commenced 24 hours after last dose of Dalteparin given Not pregnant or breast feeding Stop concomitant antiplatelet/anticoagulant/NSAID No antiphospholipid syndrome If on antiplatelets post ACS or PCI/stents do not stop - must No bleeding disorder or increased risk of bleeding discuss with Cardiology. No liver disease with cirrhosis and/or coagulopathy Follow up at 6-12 weeks for review and to decide on duration of Not taking the following medications therapy. CYP3A4 inhibitors (eg triazole and imidazole antifungals [except Thrombophilia testing is not indicated in the acute setting. Refer fluconazole], protease inhibitors [HIV antiviral drugs])

Warfarin therapy

to current BCSH guidelines if needed.

- Patient has daily INRs, dalteparin injections and adjustment of warfarin dosage as per Fennerty regime (See NHS Lothian Antithrombotic Guideline) until patient has had 5 days of dalteparin and INR has been above 2.0 for 2 days.
- Ensure patient has warfarin counselling and is not pregnant.

John's wort)

No

- Ensure warfarin tablets and yellow anticoagulant book issued and checked and patient records daily INR and warfarin dose in this.
- Follow up at 6-12 weeks for review and to decide on duration of therapy.

CYP3A4 inducers (eg rifampicin, phenytoin, carbamazepine, St.

• Thrombophilia testing is not indicated in the acute setting. Refer to current BCSH guidelines if needed.